Bertis Supports the 9th Annual Kimchi-Making Donation Event Hosted by the Union of Korea Breast Cancer Patient- Sharing warmth this winter by delivering homemade kimchi to more than 300 breast cancer patients nationwide[Photo] Bertis employees participate in making kimchi with volunteers at the “9th Annual Kimchi-Making Donation Event” in Icheon, Gyeonggi Province.Bertis, a proteomics-based precision medicine company (co-CEOs Dong-young Noh and Seung-man Han), announced that it supported the “9th Annual Nationwide Kimchi-Making Donation Event for Breast Cancer Patients,” organized by the Union of Korea Breast Cancer Patient (UKBCP).UKBCP is a non-profit organization registered under the Ministry of Health and Welfare dedicated to protecting the rights and improving the quality of life of breast cancer patients. The organization runs patient community groups, operates rest shelters, and offers various welfare support services. As part of its ongoing patient support efforts, this year’s kimchi-making event was held on November 18–19 at the UKBCP shelter in Icheon, Gyeonggi Province. Kimchi prepared directly by UKBCP members and volunteers was delivered to more than 300 breast cancer patients nationwide to help them prepare for the winter season.Through this sponsorship, Bertis supported the healthy recovery of breast cancer patients and contributed to a meaningful act of sharing. Bertis is the company behind MASTOCHECK®, the world’s first proteomics-based blood test for the early detection of breast cancer, and continues to engage in patient-focused initiatives alongside its technological advancements.Seung-Ran Choi, UKBCP President, said, “This kimchi donation event is more than just sharing food—it provides patients an opportunity to feel warmth and encouragement throughout their healing journey. Thanks to the interest and support from companies like Bertis, many patients will be able to spend this winter with comfort and hope.”Seung-man Han, CEO of Bertis, stated, “We are honored to join UKBCP in this meaningful event for breast cancer patients. As a biotech company, Bertis will continue to uphold its social responsibility and remain committed to supporting patients and contributing to a healthier society through various community initiatives.”

Bertis Enables Hanmi’s Breakthrough Obesity Drug Mechanism Discovery with Advanced Proteomics Expertise- Hanmi Pharmaceutical’s ‘HM17321’ captures global attention at the European Association for the Study of Diabetes (EASD) for its dual mechanism of increasing muscle mass while reducing fat- Bertis’ ‘PASS’ has overcome limitations in skeletal muscle proteome analysis through advanced mass spectrometry and data interpretation, providing scientific evidence for HM17321’s mechanism of action- Global proteomics market projected to reach KRW 95 trillion; utilization in clinical research and drug development rapidly expandingBertis, a proteomics-based precision medicine company (co-CEOs Dong-young Noh and Seung-man Han), announced that its advanced proteomics platform, PASS (Pan-omics Analysis Service & Solution), played a key role in uncovering the molecular mechanism of Hanmi Pharmaceutical’s novel obesity drug candidate, HM17321.At the 61st European Association for the Study of Diabetes (EASD 2025), held in Vienna, Austria (September 15–19), Hanmi Pharmaceutical presented six preclinical studies on three investigational obesity drug candidates, including HM17321.Among these, HM17321—powered by Bertis’ PASS (Pan-omics Analysis Service & Solution)—stood out as an innovative first-in-class obesity treatment candidate demonstrating a dual mechanism that promotes muscle growth while selectively reducing fat, addressing one of the most persistent challenges in obesity therapeutics.PASS is Bertis’ customized proteomics analysis service that integrates the company’s large-scale mass spectrometry infrastructure and bioinformatics expertise. In the HM17321 study, Bertis successfully identified high-resolution changes in both proteome and phosphoproteome profiles in muscle and adipose tissues.Through close collaboration with Hanmi’s R&D Center, the analysis revealed activation of mTOR signaling and protein synthesis pathways and identified changes in satellite cell–related proteins in muscle tissue, while uncovering lipid metabolism and anti-inflammatory protein regulation patterns in adipose tissue. The resulting proteomic data served as key molecular evidence supporting HM17321’s mechanism of action and its translational potential in clinical applications.In particular, this analysis utilized Thermo Fisher Scientific’s high-resolution mass spectrometer ‘Orbitrap Astral’ along with Bertis’ proprietary fractionation technology (COFFER), achieving approximately 20% higher protein identification coverage compared to previous studies. As a result, more than 10,000 proteins were identified from skeletal muscle samples, enabling quantitative assessment of key protein changes within activated signaling pathways. Given the high complexity that makes phosphoproteome analysis in skeletal muscle particularly challenging, this achievement represents an unprecedented level of analytical coverage—demonstrating the high sensitivity and interpretive power of Bertis’ PASS platform.Meanwhile, the global proteomics market is experiencing rapid growth. According to MarketsandMarkets, the market—valued at approximately USD 36.8 billion in 2023—is expected to grow more than 14% annually to reach USD 72.9 billion by 2028. The clinical diagnostics segment, which accounts for nearly half of the market, is projected to expand to USD 37.7 billion by 2028, reflecting the increasing demand for proteomics in drug mechanism research and biomarker discovery. In this context, platforms such as PASS are gaining recognition as critical infrastructure for shortening research timelines and reducing risks for pharmaceutical and biotech companies.Un-beom Kang, Ph.D., Head of the Biomarker Research Institute at Bertis, commented, “PASS is currently collaborating with multiple pharmaceutical and biotech companies worldwide to support precision diagnostics and drug development research. This project clearly demonstrates PASS’ capability to directly contribute to elucidating drug mechanisms, and we expect proteomics analysis to play an even more pivotal role in a broad range of future studies.”

Bertis’ 'MASTOCHECK®' Promotes the Importance of Regular Breast Cancer Screening at the 2025 Pink Run- Participated as a sponsor in the October Breast Cancer Awareness Month event- Operated the MASTOCHECK® promotional booth highlighting the need for regular breast cancer screening[Photo] Participants visit Bertis’ MASTOCHECK® booth at the Pink Run event to join interactive activities.On October 13, Bertis, a company specializing in proteomics-based precision medicine technology (led by CEOs Dong-young Noh and Seung-man Han), announced that it participated in the 2025 Pink Run held on October 12 at Peace Plaza in Sangam World Cup Park, introducing its breast cancer early-detection blood test, MASTOCHECK®, and promoting the importance of regular breast cancer screening.The Pink Run, part of the Pink Ribbon Campaign, is jointly hosted by the Korea Breast Cancer Foundation, the Korean Breast Cancer Society, the Korean Cancer Association, and the Seoul Foundation of Women & Family. The event aims to raise public awareness of breast health and encourage women to practice regular breast cancer screening. Celebrating its 25th anniversary this year, the event gathered about 5,000 pre-registered participants who shared their commitment to breast health. Participants took part in 5 km and 10 km runs, as well as various on-site programs and events designed to highlight the importance of early detection and regular screening for breast cancer.In celebration of Breast Cancer Awareness Month, Bertis joined the event as a sponsor and operated a promotional booth at the venue. The booth featured MASTOCHECK® and provided information on the importance of regular breast cancer screening and testing methods through quiz events, drawing strong interest and engagement from participants.MASTOCHECK® is the world’s first commercialized proteomics-based blood test for early breast cancer detection, developed by Bertis. Having been approved by the Ministry of Food and Drug Safety (MFDS) for its validated effectiveness in detecting early-stage (Stage 0–2) breast cancer, MASTOCHECK® offers a convenient, non-invasive blood test option free from radiation exposure or discomfort. It also allows screening for women in their 20s and 30s who are not typically recommended for mammography. The test is currently available at more than 550 hospitals and health screening centers across Korea.Seung-man Han, CEO of Bertis, said, "Following our participation in last year’s Pink Ribbon campaign, we are honored to take part in this year’s Pink Run to help raise public awareness of breast health and the importance of regular screening. Bertis will continue to contribute to the early detection and awareness of major diseases, including breast cancer, through innovative early-diagnosis solutions such as MASTOCHECK®.”

Bertis and Innoquest Diagnostics Sign a Strategic Partnershipto Bring Bertis’ Technology to the Southeast Asian Market[Image] Innoquest Diagnostics & Bertis logoOn July 3, Bertis, a company specializing in proteomics-based precision medicine technology, led by CEOs Dong-young Noh and Seung-man Han, announced the signing of a strategic partnership agreement with Innoquest Diagnostics, the leading clinical diagnostics laboratory in Singapore.Innoquest Diagnostics is a leading independent and internationally accredited diagnostics provider in Singapore. It is a subsidiary of Pathology Asia, one of Southeast Asia’s largest networks of independent laboratories. With operations across Singapore, Malaysia, Vietnam, the Philippines, Thailand, Indonesia, and Australia, Pathology Asia collectively serves a population of over 500 million. With its large-scale infrastructure and regional reach, the group is well-positioned as a key enabler of accessible, high-volume cancer screening throughout Southeast Asia. This partnership aims to establish the local testing infrastructure for Bertis’ proteomics-based blood test for early breast cancer detection, while laying the foundation for service expansion into new Asia-Pacific markets.Under this strategic collaboration, Bertis will provide its mass spectrometry-based proteomic analysis technology, which powers its CHECK series of blood-based diagnostic tests, including MASTOCHECK® as well as additional pipeline tests targeting other cancers, such as pancreatic and ovarian cancer.Innoquest Diagnostics will operate the test at its facilities and handle its distribution and commercialization in Singapore. This collaboration enables Bertis to establish a strong operational footprint to meet the growing demand for advanced diagnostic solutions. The two companies plan to sequentially expand the service through the Pathology Asia network of laboratories into other Southeast Asian countries including Indonesia, Malaysia, Thailand, Vietnam, the Philippines, Australia, and Hong Kong.Through this partnership, Bertis aims to accelerate the localization and adoption of its cancer early detection technologies, further strengthening the global competitiveness of its proteomics-based precision diagnostic platform. Southeast Asia presents a significant unmet need for early cancer detection given high cancer incidence rates coupled with low screening coverage. Blood-based diagnostics such as MASTOCHECK® offer a compelling, accessible solution for this region.Thomas Halusa, CEO of Innoquest Diagnostics, added, “We are excited to partner with Bertis to bring innovative, blood-based cancer screening tools to Singapore and the broader region. This collaboration aligns with our commitment to advancing accessible, science-led diagnostic solutions and reinforces our role as a region's partner of choice for global medical technology innovators.”Seung-man Han, CEO of Bertis, stated, “This partnership reflects the trust and executional experience we’ve built in Singapore around proteomics technologies. More than just a distribution deal, it marks a strategic entry into the Southeast Asia cancer diagnostics market based on our proprietary technology. We hope that MASTOCHECK® and our broader portfolio of proteomics-based early detection solutions will make a meaningful contribution to improving cancer care across diverse healthcare systems.”

Bertis to Participate in BIO KOREA 2025,Showcasing Panomics Analysis Service & Solution ‘PASS’- Highlights recent research achievements using PASS, including exosome and PROTAC-based therapeutic studies- Offers customized analysis consultations for drug discovery and basic research in the biopharmaceutical fieldOn May 2nd, Bertis, a company specializing in proteomics-based precision medicine technology (led by CEOs Dong-young Noh and Seung-man Han), announced its participation in BIO KOREA 2025, taking place at COEX, Seoul, from May 7 to 9. At the event, Bertis will operate a promotional booth to showcase its mass spectrometry-based omics analysis service, PASS (Pan-omics Analysis Service & Solution).Celebrating its 20th anniversary this year, BIO KOREA is Korea’s largest biohealth exhibition and conference, co-hosted by the Korea Health Industry Development Institute (KHIDI) and Chungcheongbuk-do Province. The event serves as a platform for global healthcare professionals to share the latest industry trends and explore international collaboration and business opportunities. During the exhibition, Bertis will offer on-site consultations to domestic and international researchers and R&D professionals, introducing the customized analytical services and bioinformatics solutions provided by PASS.PASS is an integrated omics analysis solution that combines advanced mass spectrometry-based proteomics with bioinformatics expertise, supporting diverse needs in pharmaceutical and biotech research, including drug discovery and early-stage development. PASS has recently gained recognition for its data quality and customized consulting capabilities through successful project outcomes, including publication in top-tier journals and regulatory approvals. Notably, a study on acute liver failure using exosome therapeutics was published in Nature Communications in February, and a PROTAC (PROteolysis-Targeting Chimera)-based study for promoting bone regeneration was featured in Advanced Science in March. In April, exosome-based acute ischemic stroke therapy developed by S&E Bio—supported by protein characterization and quality assessment through PASS—received Korea’s first IND approval for a clinical trial in this therapeutic area.Seong-jun Park, Director of the PASS Center at Bertis, stated, “Through our participation in BIO KOREA 2025, we look forward to sharing our analytical capabilities and recent project achievements with domestic and international stakeholders in basic and translational research. We will continue enhancing our technologies and consulting expertise to serve as a reliable partner in the biopharmaceutical industry.”Bertis will provide in-depth consultations regarding the PASS service at Booth F19 in Hall C of COEX.

Bertis Expands MASTOCHECK® into Thailand and the Philippines- Bertis signs a supply agreement with LifeStrands, an innovative clinical genomics company, to launch MASTOCHECK® testing in Thailand and the Philippines- High expectations for rapid adoption of MASTOCHECK®, driven by strong interest from local medical professionals and LifeStrands' extensive network[Image] Analyzing samples sent from a medical institution in the Philippines for MASTOCHECK® testingOn April 21, Bertis, a company specializing in the development of proteomics-based precision medicine technology (led by CEOs Dong-young Noh and Seung-man Han), announced the launch of MASTOCHECK®, a blood test for early breast cancer detection, in Thailand and the Philippines.Bertis has signed a supply agreement with LifeStrands, an innovative clinical genomics company, to initiate MASTOCHECK® testing in the two countries. The sales and marketing of MASTOCHECK® in Thailand and the Philippines will be handled by LifeStrands, which is headquartered in Singapore. The agreement was finalized with LifeStrands on January 10th.LifeStrands, the genomics and life sciences subsidiary of Pathology Asia Group—a leading diagnostic service provider in Southeast Asia—was established in June 2020 and specializes in clinical and translational genomics and provides genomic testing services through its partnered hospital networks across Singapore, Thailand, Philippines, Malaysia, Indonesia and Australia.MASTOCHECK® is the world's first proteomics-based blood test for early breast cancer detection developed by Bertis. It diagnoses breast cancer by quantifying three blood-based protein biomarkers and analyzes the results using a patented algorithm. The test has proven efficacy in screening for early-stage breast cancer (stages 0-2) and has been approved as an in vitro diagnostic medical device by the Ministry of Food and Drug Safety. It is currently used in over 500 medical institutions in Korea and has also entered the Singapore market.Seung-man Han, CEO of Bertis, stated, "We are excited to introduce MASTOCHECK® in Thailand and the Philippines through our partnership with LifeStrands, a key player in Southeast Asia. We anticipate rapid adoption in the region, supported by strong interest from local medical professionals and LifeStrands' robust network."Asian women are more likely to have dense breasts compared to Western women. In dense breast tissue, the high proportion of glandular tissue can obscure tumors on mammogram images, making early detection more difficult. As a blood-based diagnostic tool, MASTOCHECK® demonstrates high accuracy even in women with dense breasts. It also ensures consistent results by eliminating variations caused by subjective interpretation and is suitable for young women, women of childbearing age, and pregnant women.

Bertis Signs MOU with COSMAX for Joint Research in Skin Proteomics Analysis-Collaboration to begin with establishing skin proteomics analysis technology, expanding into joint development of skin biomarker panelsand related business initiatives-Expanding the application of proteomics into personalized skin aging care<Photo: From left, COSMAX Group Chairman Kyung-soo Lee, Bertis Co-CEO Dong-young Noh, and Bertis Co-CEO Seung-man Han pose for a commemorative photo during the MOU signing ceremony held at COSMAX’s headquarters in Seongnam, Gyeonggi Province, on April 11.>On April 15, Bertis, a company specializing in proteomics-based precision medicine technology (led by CEOs Dong-young Noh and Seung-man Han), announced the signing of a memorandum of understanding (MOU) with COSMAX, a global leader in cosmetic ODM (Original Development and Manufacturing), to collaborate on research in skin proteomics analysis.Under this MOU, the two companies plan to collaborate comprehensively in areas including academic exchange related to skin proteomics analysis technology, joint development of skin biomarker panels, and co-development, production, and commercialization of cosmetic ingredients and formulations.Skin proteomics analysis utilizes advanced proteomic technologies to precisely identify and quantify proteins expressed in skin tissues or cells. This allows for the detailed understanding of physiological changes in the skin and its biological responses to external stimuli. It can be applied to diagnose skin aging, damage, regeneration, and irritation, as well as to develop personalized skincare and cosmetic solutions.COSMAX, the world’s top cosmetic ODM company, possesses world-class capabilities in utilizing biological resources and was the first in the world to commercialize microbiome-based skincare in 2019. The collaboration will start with building a foundation for skin proteomics, with plans to expand into database construction, protein profiling by cause of aging, and diagnostic software development.Seung-man Han, CEO of Bertis, stated, "We at Bertis possess unmatched expertise in discovering biomarkers for cancer, aging, and other major diseases through proteomics, and in developing diagnostic and analytical solutions based on those findings. We are excited to collaborate with COSMAX to advance our capabilities in skin proteomics and broaden the application of proteomics technology into personalized skin aging care."Bertis is a leading company in commercializing proteomics technology based on its proprietary ProteoID platform, which spans from protein data analysis to product and service development. In 2019, the company launched MASTOCHECK®, the world’s first proteomics-based blood test for the early detection of breast cancer. Additionally, Bertis offers PASS (Pan-omics Analysis Service & Solution), an integrated omics analysis solution that provides customized results tailored to the needs of clients across the biotech and CDMO industries—from basic R&D to novel modality drug development.

Bertis Appoints Global Life Sciences Innovation and Sustainability ExpertDr. David Berryto Scientific Advisory Board - Dr. David Berry, a global authority in innovation and sustainable management, has participated in founding over 30 companies, including Moderna- First collaboration with a Korean company as a Scientific Advisory Board member, supporting Bertis’ global expansion[Image] Dr. David BerryOn February 6th, Bertis, a company specializing in proteomics-based precision medicine technology (led by CEOs Dong-young Noh and Seung-man Han), announced that it has appointed Dr. David Berry, a world-renowned authority on innovation and sustainable management in the life sciences, as a member of its Scientific Advisory Board (SAB).Dr. David Berry, who received hisMD from Harvard Medical School and PhD in Biological Engineering from the Massachusetts Institute of Technology (MIT), holds over 200 patents in life sciences and other fields. He has co-founded more than 30 companies, including 7 valued at over $1 billion. Notably, Dr. Berry contributed to the establishment of Moderna, a company developing mRNA technology-based vaccines and therapeutics.As a globally recognized expert in innovation and sustainable management, Dr. Berry currently serves as an Emeritus member of the Leadership Council for the United Nations Sustainable Development Solutions Network (UN SDSN). His achievements have been widely recognized: he was named an Innovator of the Year in 2007 by the MIT Technology Review, a 2014 Young Global Leader by the World Economic Forum, and one of 12 Innovators Helping Reshape Reality by the U.S. State Department.Dr. Berry's appointment to Bertis' Scientific Advisory Board draws significant attention as it marks his first collaboration with a Korean company. Bertis aims to leverage Dr. Berry's extensive experience and expertise as an innovation leader, inventor, and entrepreneur to formulate its global expansion strategy and establish itself as a leading company in proteomics-based precision medicine technology on the world stage. Dr. David Berry stated, "Bertis possesses world-class proprietary technology in clinical proteomics and is leading the realization of precision medicine through early disease diagnosis and personalized treatment activation. I look forward to contributing to the global dissemination of Bertis' proteomics-based precision medicine technology and driving innovation in the medical field." Seung-man Han, CEO of Bertis, emphasized, "Since ourfounding in 2014, Bertishas built a globally competitivetechnological framework through continuous challenges and achieved commercialization and technological development in proteomics, includingmulti-protein biomarker-basedblood tests. Weexpect our collaboration withDr. Berry to be a significantboost in elevating Bertis to the next level as aglobally competitive precision medicine technology company, building on the technological achievements we've accumulated overthe past decade."

Bertis Participates in '2024 Pink Festival' to Raise Awareness of the Importance of Regular Breast Cancer Screenings- Participating as an event sponsor, operating a promotional booth to enhance breast health awareness and deliver useful information on regular breast cancer screenings, including MASTOCHECKOn October 10th, Bertis, a company specializing in proteomics-based precision medicine technology (led by CEOs Dong-young Noh and Seung-man Han), announced that it will participate as a sponsor in the 2024 Pink Festival held at Yongsan Park on October 13th to conduct promotional activities highlighting the importance of regular breast cancer screenings.The Pink Festival, held as part of the Pink Ribbon Campaign, is co-hosted by the Korea Breast Cancer Foundation, the Korean Breast Cancer Society, and the Korean Cancer Association to encourage greater awareness of breast cancer and the importance of regular screenings among women. Now in its 24th year, the event will be attended by 1,000 pre-registered participants and will feature various breast health programs, including a 3km run, GX programs, consultations with medical professionals, and a mini concert.In celebration of Breast Cancer Awareness Month in October, Bertis will sponsor the 2023 Pink Festival and operate a promotional booth at the event. The booth will feature a quiz event aimed at attendees, highlighting the importance of early breast cancer detection and providing useful information about regular breast cancer screenings, including Bertis's early detection blood test, MASTOCHECK®.MASTOCHECK® is the world’s first proteomics-based early detection test for breast cancer, launched by Bertis in 2019. It has demonstrated its effectiveness in diagnosing stage 0 to 2 breast cancer and received approval from the Ministry of Food and Drug Safety in 2019. As a blood test, MASTOCHECK® can be performed on women in their 20s and 30s, for whom mammography is not recommended, and about 100,000 tests were conducted in 2023 alone. MASTOCHECK® is currently implemented in more than 500 hospitals and health screening centers in Korea.Seung-man Han, CEO of Bertis, said, “We participated in the Pink Festival to inform more women, including those in their 20s and 30s of the importance of breast health and to encourage regular breast cancer screenings. We will do our best to continuously contribute to activating early diagnosis by raising awareness and providing useful solutions based on easily accessible blood tests for the early detection of major diseases, including breast cancer, in medical settings.”

Bertis Presents Blood Test Model for Pancreatic Cancer Diagnosis with 92% Accuracy Based on 13 Biomarkers- Presenting an exploratory trial result for early diagnosis of PDAC using LC-MS technology effective for disease screening- Conducting a confirmatory trial for pancreatic cancer’s early diagnosis blood test ‘Panccheck,’ having secured blood samples from 513 individuals, including 220 pancreatic cancer patientsOn September 24th, Bertis, a company specializing in the development of proteomics-based precision medicine technology (led by CEOs Dong-young Noh and Seung-man Han), announced that the findings on protein biomarkers for the diagnosis of Pancreatic Ductal Adenocarcinoma (PDAC) were published in the September issue of the prestigious international journal ‘Molecular & Cellular Proteomics.’Pancreatic cancer is highly lethal due to its asymptomatic nature in the early stages, making early detection extremely challenging. Most patients are diagnosed at advanced stages, resulting in very low survival rates. According to data released by the Korea Central Cancer Registry in 2024, the 5-year cancer relative survival rate for pancreatic cancer from 2017 to 2021 is only 15.9%, making it the most difficult to treat among the top 10 cancers. In particular, PDAC, which accounts for more than 90% of pancreatic cancer, is considered one of the most lethal cancer types with a 5-year average survival rate of less than 10%.Currently, the blood biomarker Carbohydrate Antigen 19-9 (CA19-9) is used for pancreatic cancer screening, but its usefulness is considered limited due to its low positive predictive value. This study focused on developing an effective diagnostic method for PDAC screening based on Liquid Chromatography-Mass Spectrometry (LC-MS) technology, which allows for the simultaneous and precise quantification of multiple protein biomarkers in blood and is effective for disease screening tests that require economical and rapid analysis of a large number of samples.In this study, the Bertis research team selected 12 protein biomarkers that were differentially expressed in PDAC patients compared to a control group of healthy individuals and/or those with benign pancreatic diseases, using mass spectrometry and bioinformatics techniques. They then developed a Multi-Marker Panel consisting of 13 biomarkers combined with CA19-9. In the next step, they developed a diagnostic test model with improved performance and robustness using machine-learning technology and evaluated its diagnostic performance for PDAC screening. As a result, the model demonstrated an accuracy of 92% for all stages of PDAC and stage 1 to 2 PDAC, showing improved diagnostic performance in all cases compared to when CA19-9 was used alone.Un-beom Kang, Head of the Bertis Biomarker Research Institute and co-leader of the research, stated, “The results of this study represent a significant achievement in providing a useful diagnostic model for the early detection of pancreatic cancer, a particularly hard-to-treat cancer, based on Bertis’ advanced technologies in proteomics, bioinformatics, and machine learning. We are committed to follow-up research and development to ensure that healthcare professionals and patients can utilize this technology in clinical settings, thereby facilitating early diagnosis of pancreatic cancer.”Bertis is promoting the commercialization of its blood test, Panccheck®, to aid in the early diagnosis of pancreatic cancer based on this research achievement. Currently, a confirmatory trial is underway, with blood samples secured from 513 individuals, including 220 pancreatic cancer patients, in preparation for approval from the Ministry of Food and Drug Safety. Additionally, Bertis is developing an early diagnosis test for ovarian cancer, which has the highest mortality rate among gynecological cancers and lacks effective early detection methods. The marker panel development is complete, and a clinical trial for algorithm enhancement are planned.Seung-man Han, CEO of Bertis, emphasized, “Bertis is working to introduce multi-marker diagnostic solutions with improved accuracy based on more biomarkers for major diseases by adding the latest machine learning technology to the proteomics technology we have developed over the past decade. Building on our capability to commercialize Mastocheck, the world’s first proteomics-based blood testing for early breast cancer diagnosis, we are committed to providing effective early diagnosis solutions for hard-to-treat diseases like pancreatic cancer in clinical practice.”Meanwhile, Bertis combines proteomics and bioinformatics to develop innovative biomarkers for cancer and other major diseases, as well as provides diagnosis and analysis solutions. It succeeded in commercializing proteomics technology with Mastocheck®, the blood testing solution for early breast cancer diagnosis, and PASS (Pan-omics Analysis Service & Solution), an omics analysis solution. Bertis continues to conduct research on early diagnosis solutions for major diseases.

Bertis Joins the Ministry of Science and ICT’s‘Development of Technologies for Spatial Proteomics-BasedMulti-Omics Analysis’ Project- 6 institutions participate with a total research budget of approximately 9 billion KRW over 4 years and 6 months-Bertis participates in securing global-level spatial proteomics technologies with its expertise in proteomics-based biomarkersOn September 6, Bertis, a company specializing in the development of proteomics-based precision medicine technology (led by CEOs Dong-young Noh and Seung-man Han), announced its participation as a research institution in the ‘Development of Materials and Component Technologies for Spatial Proteomics-Based Multi-Omics Analysis’ project (Project No. RS-2024-00454407), led by the Ministry of Science and ICT and the National Research Foundation of Korea.This project is part of the ‘2024 Nano and Materials Technology Development Project’ initiated by the Ministry of Science and ICT and the National Research Foundation of Korea. It aims to secure global-level technologies that will drive the creation of new industries and advance key sectors, while also expanding research infrastructure and promoting commercialization.Bertis will collaborate with the institution in charge of research, University of Ulsan College of Medicine, Meteor Biotech, Korea Animal Model Archive, Future Medicine Research Institute of CHA Bundang Medical Center of CHA University, and the Korea Basic Science Institute to form the 'Spatial Proteomics Technology Development Research Consortium.' The consortium will undertake the project to develop spatial proteomics technologies for multi-omics, with a total research budget of 9 billion KRW, until December 2028.Spatial proteomics technology is a field that studies the spatial distribution and interactions of proteins within tissues. No commercialized technologies for spatial proteomics analysis exist, and single-cell preprocessing methods are being used as alternatives. This project will develop novel materials and foundational technologies for protein digestion, which are currently unavailable in spatial proteomics processes. The goal is to establish the first global analysis platform, from tissue separation to diagnosis, build databases, develop AI software, and create biomarkers for various cancers.Bertis, recognized for its technological prowess in developing and utilizing proteomics-based biomarkers, will be responsible for establishing LC-MS analysis conditions using single-cells, developing spatial proteomics-specific preprocessing materials and POC (Proof of Concept), creating quality control software for fragmented tissue proteomics analysis platforms, and developing and training AI algorithms through pathology image analysis.Kyunggon Kim, a professor in the Department of Digital Medicine at the University of Ulsan College of Medicine, head of the institution in charge of research, stated, "Spatial multi-omics is increasingly recognized as a key platform for translational research and new drug development. However, spatial proteomics is a field that demands advanced technology and material development. We are excited to collaborate with outstanding government-funded research institutions, hospitals, and companies with core technologies, such as Bertis and Meteor Biotech to conduct challenging research.”Un-beom Kang, Head of Bertis Biomarker Research Institute and co-leader of the research, explained, “The field of proteomics has high technological utility and remarkable growth within the biotech industry, accompanied by intense global competition to secure technological superiority and foundational technologies for disease diagnosis and treatment. As a leader in the proteomics industry with expertise in commercializing technology and applying AI, Bertis is dedicated to achieving significant results in the development of spatial proteomics technologies through collaboration with leading domestic research institutions."Meanwhile, Bertis has established its proprietary analysis system for single-cell proteomics research and is accelerating the advancement of proteomics-based precision medicine technologies by utilizing AI. The company is enhancing the accuracy of early diagnostic solutions for breast cancer, pancreatic cancer, and ovarian cancer through machine learning-based algorithms. It is also developing the SAN (Spectrum is All you Need) model, which uses large language models (LLM) to analyze protein distribution data and extract health information related to the presence or absence of target diseases.

Bertis and Rokit Genomics Sign MoU for Collaboration on Proteomics and Genomics Analysis Services - Collaborating on single-cell proteomics and genomics analysis services to provide single-cell multi-omics analysis services and advance joint technology development <Photo: Bertis CEO Seung-man Han (left) and Rokit Genomics CEO Tae-woo Kwon commemorate the signing of the MoU.> On August 26th, Bertis, a company specializing in the development of proteomics-based precision medicine technology (led by CEOs Dong-young Noh and Seung-man Han), announced that it signed a Memorandum of Understanding (MoU) with Rokit Genomics, a single-cell analysis company (led by CEOs Tae-woo Kwon and Yoon-Ki Gil). Under this MoU, Bertis and Rokit Genomics plan to collaborate on the development and marketing of proteomics and genomics analysis services based on their expertise in single-cell analysis technology. They also will work together on future joint technology development. Single-cell analysis is a technique that distinguishes biological characteristics at the level of individual cells. It enables high-sensitivity and high-resolution analysis of rare cells or low-expressed genomics and proteomics. This method is utilized in various research fields including cancer, Alzheimer's, autoimmune diseases, and infectious diseases. The single-cell analysis market is expected to grow significantly, reaching approximately 19 trillion KRW globally by 2030. Single-cell proteomics analysis is a technology that qualitative and quantitative analysis of proteins at the single-cell level. This technique allows detailed analysis of disease-specific proteins, minimizing the loss of cellular diversity information that can occur in tissue or cultured cell analyses. This technology is expected to advance the application of precision medicine through cell-specific analysis. Bertis, which has secured the technology to analyze the proteome of trace samples through next-generation mass spectrometry technology, offers single-cell proteomics analysis of over 5,000 proteins and has launched Korea's first single-cell proteome profiling service based on this cutting-edge technology. Rokit Genomics provides customer-specific analysis services using single-cell genomics sequencing. Rokit Genomics focuses on cell heterogeneity, rare cells, cell lineage relationships, and biomarker discovery by analyzing genomic data collected from individual cells. Leveraging extensive experience with samples from human tissues to plants and animals, Rokit Genomics performs analyses across requests. Kwon Tae-woo, the CEO of Rokit Genomics, stated, “With the rise of genomics and proteomics technologies, there is an increasing demand for combined analytical methods in drug discovery and candidate development. Our collaboration with Bertis, which possesses expertise in proteomics analysis, will be a milestone in expanding Rokit Genomics' multi-omics analysis capabilities. We expect to lead the popularization of single-cell analysis through advanced customer-specific consulting.” Seung-man Han, the CEO of Bertis, emphasized, “As a leader in proteomics technology, we have equipped ourselves with the latest equipment and expertise to offer single-cell proteomics technology to domestic researchers. Through this service collaboration with Rokit Genomics, a pioneer in single-cell sequencing, we hope to raise awareness of single-cell proteomics analysis among bioindustry and academic researchers and to expand our collaborative technology development.” Furthermore, Bertis’ omics analysis solution, PASS (Pan-omics Analysis Service & Solution), provides customized proteomics analysis solutions for biomarker discovery, validation, drug research and development, and production based on client’s needs. The service caters to a range of clients, including biotech and CDMO enterprises developing new modality drugs, and has completed 103 projects for 54 clients as of July 2024, driven by satisfaction with data quality and customized consulting.

Bertis to Participate in Korea's Largest Proteomics Conference, KHUPO 2024 - Poster presentation on research outcomes in biomarker candidates for prostate cancer diagnosis, and an educational lecture on QC and interpretation of mass spectrometry-based proteomics data- Setup of a promotional booth from June 25 to 27 to introduce the mass spectrometry-based omics analysis solution PASS, and its customized peptide synthesis solution, PEPS PRO. On June 25th, Bertis, a company specializing in the development of proteomics-based precision medicine technology (led by CEOs Dong-young Noh and Seung-man Han), announced that it will participate in 'KHUPO 2024 YEOSU (KHUPO 2024)', the largest domestic proteomics conference hosted by The Korean Human Proteome Organization (KHUPO). <Image: Logos of KHUPO and Bertis> KHUPO 2024, to be held from June 25 to 27 at the Yeosu Expo Convention Center, is expected to be a platform for sharing new research achievements and innovative technologies in the field of proteomics under the theme "PROUD: PROteomics Unlimited Desire." As a leading domestic company in the proteomics field, Bertis will present research achievements, conduct educational sessions, and operate a promotional booth during KHUPO 2024.Dr. Jin-Young Cho from the Biomarker Research Team at Bertis R&D division will present a poster on "Novel Diagnostic Biomarkers for Prostate Cancer Discovered Using a Mass Spectrometry-Based Pipeline" on Wednesday, the 26th at 11:45 AM, and Thursday, the 27th at 11:30 AM. <Image: Discovery process of PCa biomarker candidates>Prostate Cancer(PCa) can often be detected by testing the levels of Prostate-Specific Antigen (PSA) in blood. However, the level of PSA is also rise in cases of benign prostatic hyperplasia and prostatitis, necessitating a more accurate diagnostic test specifically for PCa. In this study, the Bertis team used liquid chromatography data-independent acquisition tandem-mass spectrometry (LC-DIA-MS/MS) to analyze the human serum of 50 healthy controls (HCs), 42 individuals with benign conditions, and 90 patients with PCa. The aim was to discover potential biomarkers for PCa diagnosis. They identified 24 differentially expressed proteins (DEPs) in PCa patients compared to healthy controls and those with benign conditions. In addition, bioinformatic analysis on public data of prostate cancer-associated biomarkers and prognosis before and after treatment, a list of 50 proteins was created. Takes together, a total of 74 serum proteins were selected as potential prostate cancer biomarker candidates.In the education session, Dr. Sunghyun Huh, Head of the Bioinformatics Team at Bertis R&D division will deliver a lecture titled “Interpretation of Mass Spectrometry-Based Proteomics Data for Biological Research”. The session will introduce the analysis, processing, and interpretation of mass spectrometry-based proteomics data, covering relevant research examples. The lecture is scheduled for Wednesday, the 26th, at 9:00 AM in the 1st floor lecture hall, as the first session of ‘Education Session 3: Proteomics meets AI’During the event, Bertis will operate a promotional booth to showcase its mass spectrometry-based omics analysis solution, PASS (Pan-omics Analysis Service & Solution), alongside its customized peptide synthesis service, PEPS PRO. PEPS PRO provides synthesis services for customized peptides, PNAs, and various organic compounds utilizing the company’s GMP facilities and highly skilled professionals, ensuring high-quality products at competitive prices. The company plans to utilize the KHUPO 2024 platform to initiate a marketing campaign to promote PEPS PRO.Seung-man Han, CEO of Bertis, stated, "Bertis is advancing and commercializing proteomics technologies to contribute to the development of practical solutions in clinical settings for domestic biotech companies." He further emphasized, "We are dedicated to sharing innovative technologies and research outcomes to broaden the impact of proteomics in Korea and bolster technological competitiveness."

Bertis, Successful in Clinical Proteomics Technology Commercialization,Seeks International Business Partners at BIO USA 2024 - Participating in the world's largest bio conference, hosted by the Biotechnology Innovation Organization (BIO), from June 3-6 to explore business development opportunities with global bio and pharmaceutical companies. - Aiming to secure international business partners for proteomics-based early diagnostic tests through the 'Seoul Bio Forum' on June 3 and the 'Company Presentation' on June 5. On May 28th, Bertis, a company specializing in the development of proteomics-based precision medicine technology (led by CEOs Dong-young Noh and Seung-man Han), announced that it will participate in the world's largest bio conference, the 'BIO International Convention 2024' (BIO USA 2024), held at the San Diego Convention Center in the United States from June 3 to 6. At BIO USA 2024, where leading companies, research institutions, and investors from the global bio industry will gather, Bertis will conduct two company presentations. These presentations will highlight advancements in clinical proteomics technology and share the latest research developments and business achievements of Bertis, including their successfully commercialized proteomics-based early diagnostic test. Through these activities, Bertis aims to explore various business development opportunities with global bio and pharmaceutical companies. [Image] Bertis Bio USA 2024 Presentation Schedule The first company introduction presentation will take place on June 3rd, local time (PST), at 6:00 PM at the Aquillius Innovation Hub as part of the 'Seoul Bio Forum,' organized by Invest Seoul, Seoul BioHub, and others. The event is dedicated to fostering networking opportunities among Korean enterprises engaged in BIO USA 2024, venture capital firms seeking U.S. market entry and investment, and bio-tech and legal entities possessing the requisite expertise for U.S. expansion. Bertis will showcase its proteomics-based early diagnosis solution technology and outline its growth strategy. On the third day of the event, June 5th at 2:30 PM, Bertis will conduct a Company Presentation session at Hall A Company Presentation Theater4. During this session, Bertis will introduce its successfully commercialized proteomics-based early diagnostic blood test pipeline and its mass spectrometry-based omics analysis service PASS (Pan-omics Analysis Service & Solution) to global bio-pharmaceutical companies. The company aims to explore opportunities for overseas business partnerships and collaborations through this session. Seung-man Han, the CEO of Bertis, stated, "Proteomics will play a crucial role in addressing major challenges facing the medical and healthcare sectors worldwide, enabling precision medicine. Through this event, Bertis aims to share the excellence and commercial viability of our core technology. We also strive to secure business cooperation opportunities to accelerate the introduction of proteomics-based technologies and products into clinical practice." Furthermore, Bertis leads technological innovation in the field of clinical proteomics by leveraging ProteoID, its core technology framework spanning protein data analysis to product and service commercialization. In 2019, Bertis achieved the world's first commercialization of a proteomics-based early diagnostic blood test for breast cancer, MASTOCHECK®, in both domestic and Singaporean markets, conducting a cumulative total of 170,000 tests in South Korea. Currently, they are advancing the development of early diagnostic tests for pancreatic and ovarian cancers as part of their pipeline expansion.

Asia Proteomics Leader, Bertis, Participates in' Asia Summit on Global Health 2024' -Invited as the only Korean company to participate in the event hosted by the Hong Kong Special Administrative Region on May 16-17... Dr. Sangtae Kim, Chief Scientist of Informatics and AI, will attend as a speaker. -Sharing insights on proteomics technologies and applications that Asia should focus on, including early cancer detection blood tests, during the session on ‘Advancing Healthcare in Asia Through Innovation’ on May 17 [Image] Asia Summit on Global Health, Bertis Logo On May 16th, Bertis, a company specializing in the development of proteomics-based precision medicine technology (led by CEOs Dong-young Noh and Seung-man Han), announced that it will participate in the '4th Asia Summit on Global Health 2024 (ASGH 2024)', which will be held at the Hong Kong Convention and Exhibition Center (HKCEC) on May 16th and 17th.ASGH, jointly organized by the Government of the Hong Kong Special Administrative Region and the Hong Kong Trade Development Council (HKTDC), aims to promote innovative medical technology development and support investment activation to seek a more sustainable future amid global issues such as aging population, novel infectious diseases, and climate-related health threats.At ASGH 2024, key officials from the governments of China and the Hong Kong Special Administrative Region, as well as executives from global leading pharmaceutical and biotech companies and research institutions, buyers, and investors active in the Asian region, will participate. Themed ‘Innovation, Inclusion, Impact’, ASGH 2024 will compromise a series of thematic sessions focusing on the latest trends in different medical sectors. Project pitching and deal-making meetings will also be organized to facilitate business discussions and investment partnerships. Bertis, as a leader in Asia's proteomics, is invited as the only Korean company to participate. Dr. Sangtae Kim, Chief Scientist of Informatics and AI at Bertis, will speak, introducing proteomics technologies that Asia's medical industry should focus on for development, and will share insights into their applications and importance.Dr. Kim will participate in the session titled 'Advancing Healthcare in Asia Through Innovation' on May 17th. He will highlight how proteomics technology is rapidly advancing and providing opportunities for precise disease diagnosis, personalized treatment tailored to individuals, and drug target discovery. Particularly, he will introduce proteomics-based early cancer detection blood tests as an innovative technology that will bring significant changes to the healthcare industry in Asia. He plans to emphasize the importance of investing in and leading the development of proteomics technology and industry in the Asian region.Dr. Kim stated, "I am honored to have the opportunity to discuss the future direction of Asian healthcare with global leaders in Hong Kong, the hub of Asia. Proteomics technology is essential for realizing precision medicine and plays a crucial role in addressing key challenges faced by the healthcare sector in Asia. I will do my utmost to promote regional collaboration and highlight the importance of this technology in overcoming these challenges."Bertis combines more than a decade of accumulated expertise in proteomics with bioinformatics to identify biomarkers for various major diseases, including cancer. These biomarkers are then utilized in the development of diagnostic and analytical solutions. In 2019, Bertis introduced MASTOCHECK®, the world's first proteomics-based early breast cancer detection blood test. The company is currently working on developing early detection blood tests for pancreatic cancer and ovarian cancer as part of its ongoing pipeline. Additionally, Bertis is engaged in the research and development of SAN (Spectrum is All you Need) model, aiming to create an innovative health information interpretation model that can extract health insights from proteomic biological data using AI technology.